BioDelivery Sciences International, Inc. (BDSI) Receives $4.57 Average PT from Brokerages

Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) have been assigned a consensus recommendation of “Buy” from the nine brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $4.57.

Several equities analysts recently issued reports on the stock. Zacks Investment Research raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. HC Wainwright set a $5.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Monday, November 27th. Seaport Global Securities assumed coverage on shares of BioDelivery Sciences International in a research note on Friday, January 26th. They set a “buy” rating and a $5.00 price objective on the stock. Finally, Roth Capital set a $5.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Monday, November 13th.

Shares of BioDelivery Sciences International (NASDAQ BDSI) remained flat at $$2.10 on Friday. 492,000 shares of the company traded hands, compared to its average volume of 559,821. The company has a quick ratio of 1.07, a current ratio of 1.28 and a debt-to-equity ratio of 1.89. The firm has a market cap of $117.36, a PE ratio of -11.16 and a beta of 0.50. BioDelivery Sciences International has a 12-month low of $1.55 and a 12-month high of $3.60.

In other news, Director Mark A. Sirgo sold 162,509 shares of the stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $2.78, for a total value of $451,775.02. Following the completion of the sale, the director now owns 1,759,262 shares of the company’s stock, valued at $4,890,748.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark A. Sirgo sold 709,502 shares of the stock in a transaction on Friday, January 19th. The stock was sold at an average price of $2.73, for a total transaction of $1,936,940.46. Following the completion of the sale, the director now directly owns 1,759,262 shares of the company’s stock, valued at approximately $4,802,785.26. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 980,011 shares of company stock worth $2,666,275. 7.73% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Advisor Group Inc. lifted its position in shares of BioDelivery Sciences International by 42.1% in the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 13,341 shares during the last quarter. Royce & Associates LP acquired a new position in shares of BioDelivery Sciences International in the 3rd quarter worth approximately $3,814,000. EAM Investors LLC grew its stake in shares of BioDelivery Sciences International by 62.1% in the 3rd quarter. EAM Investors LLC now owns 780,635 shares of the specialty pharmaceutical company’s stock worth $2,303,000 after purchasing an additional 299,163 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of BioDelivery Sciences International in the 3rd quarter worth approximately $116,000. Finally, Krilogy Financial LLC grew its stake in shares of BioDelivery Sciences International by 28.8% in the 3rd quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock worth $395,000 after purchasing an additional 30,000 shares during the last quarter. 43.98% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “BioDelivery Sciences International, Inc. (BDSI) Receives $4.57 Average PT from Brokerages” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/20/biodelivery-sciences-international-inc-bdsi-receives-4-57-average-pt-from-brokerages.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply